Certain features of will be down for maintenance Saturday afternoon/evening, February 24th starting at 3:00 pm CT until 9:00 pm CT.

Please note that you still have telephone and email access to our local offices. We apologize for any inconvenience.

UHPLC Analysis of Intact Infliximab on BIOshell(TM) A400 Protein C4

UHPLC Analysis of Intact Infliximab on BIOshell™ A400 Protein C4


column BIOshell A400 Protein C4; 10 cm x 2.1 mm I.D., 3.4 μm particles (66825-U)
column temp. 75 °C
mobile phase [A] 70:25:5 water (0.1% TFA): acetonitrile (0.1% TFA): 1-butanol (0.1% TFA); [B] 50:45:5 water (0.1% TFA): acetonitrile (0.1% TFA): 1-butanol (0.1% TFA)
gradient 0% B to 100% B in 15 min
flow rate 0.2 mL/min
pressure 680 psi (46 Bar)
sample Infliximab, 100 μg/mL, water (0.05% TFA)
injection 5 μL
detector UV, 215 nm


Analysis Note Infliximab (brand name Remicade) is an immunosuppressive biologic drug used to treat rheumatoid arthritis, psoriatic arthritis, Crohn′s disease, and many other diseases by blocking TNF alpha which prevents an autoimmune reaction. It has a molecular weight of ~150 kDa. The BIOshell A400 Protein C4 UHPLC column yielded an efficient peak for this protein in less than five minutes.
Featured Industry Pharmaceutical (small molecule)
Legal Information BIOshell is a trademark of Sigma-Aldrich Co. LLC
suitability application for UHPLC


Related Links